1. Search Result
Search Result
Results for "

large non-structural protein 3 (nsp3)

" in MedChemExpress (MCE) Product Catalog:

395

Inhibitors & Agonists

28

Screening Libraries

15

Fluorescent Dye

32

Biochemical Assay Reagents

35

Peptides

15

MCE Kits

17

Inhibitory Antibodies

33

Natural
Products

219

Recombinant Proteins

21

Isotope-Labeled Compounds

121

Antibodies

1

Click Chemistry

23

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-150062

    SARS-CoV Infection
    SARS-CoV-2 nsp3-IN-1 (Compound 15c) is a Mac1 (SARS-CoV-2 nsp3 macrodomain) inhibitor with the IC50 value of 6.1 μM. SARS-CoV-2 nsp3-IN-1 can inhibit Mac1 ADP-ribosylhydrolase activity. SARS-CoV-2 nsp3-IN-1 demonstrates notable selectivity for coronavirus macrodomains, especially towards SARS-CoV-2 Mac1 .
    SARS-CoV-2 nsp3-IN-1
  • HY-122671

    Anion Exchangers Neurological Disease
    OB-1 is a stomatin-like protein-3 (STOML3) oligomerization blocker. OB-1 is an effective inhibitor of the self-association of Stomatin, STOML1 and STOML2, but not podocin .
    OB-1
  • HY-117411A

    KW-136 dihydrochloride

    HCV HCV Protease Infection
    Coblopasvir (KW-136) dihydrochloride is a pangenotypic non-structural protein 5A (NS5A) inhibitor. Coblopasvir dihydrochloride can be used for research of chronic hepatitis C virus infection .
    Coblopasvir dihydrochloride
  • HY-156597

    AT-752 free base

    SARS-CoV Infection
    Arbemnifosbuvir is a nidovirus DdRp-associated nucleotidyltransferase (NiRAN) domain of non-structural protein 12 (nsp12)-interfering drugs. Arbemnifosbuvir can be used for SARS-CoVs infection research .
    Arbemnifosbuvir
  • HY-150064

    SARS-CoV Infection
    SARS-CoV-2 nsp3-IN-2 is a macrodomain (Mac1) inhibitor with IC50 value of 180 μM. SARS-CoV-2 nsp3-IN-2 is a small molecule chemical probe and can be used for the research of viral .
    SARS-CoV-2 nsp3-IN-2
  • HY-163785

    SARS-CoV Infection
    1"-α-Azido-RDPr (Compound 11) is an analog of adenosine diphosphate ribose, and exhibits inhibitory efficacy against the SARS-CoV-2 nonstructural protein macodomain SARS-CoV-2 NSP3 Mac1 with an IC50 of 30 nM .
    1
  • HY-157439

    SARS-CoV Infection
    SARS-CoV-2-IN-72 (compound 12) is a potent allosteric inhibitor of the SARS-COV-2 papain-like protease domain that can trigger the degradation of NSP3 .
    SARS-CoV-2-IN-72
  • HY-117411

    KW-136

    HCV HCV Protease Infection Inflammation/Immunology
    Coblopasvir (KW-136) is a pangenotypic non-structural protein 5A (NS5A) inhibitor. Coblopasvir can be used for research of chronic hepatitis C virus infection .
    Coblopasvir
  • HY-P10403

    IGF-1R Inflammation/Immunology Cancer
    IGFBP-3 peptide is a 18-amino acid insulin-like growth factor binding protein-3. IGFBP-3 peptide binds Humanin (HY-P1928) and Hyaluronan (HY-B0633A), blocks the interaction of CD44 and hyaluronan .
    IGFBP-3 peptide
  • HY-174224

    ZINC000002782982

    SARS-CoV Infection
    Amb929 (ZINC000002782982), a nsp3 ligand, is an anti-SARS-CoV-2 agent. Amb929 inhibits SARS-CoV2-mNG replication in VeroE6 cells with an EC50 of 34.7 µM. Amb929 has limited and moderate cytotoxicity for VeroE6 cells (CC50: 281 µM). Amb929 also inhibits SARS-CoV-2-mNG replication in Human Airway Epithelium (HAE) .
    Amb929
  • HY-E70216

    Others Others
    Bsu DNA polymerase, Large fragment is a polymerase derived from Bacillus subtilis. Bsu DNA polymerase, Large fragment is a DNA isothermal amplification polymerase with chain replacement activity, which used in RPA recombinase polymerase amplification technology .
    Bsu DNA polymerase, Large fragment
  • HY-122671S

    Anion Exchangers Neurological Disease
    OB-1-d3 is the deuterium labeled OB-1 (HY-122671). OB-1 is a stomatin-like protein-3 (STOML3) oligomerization blocker. OB-1 is an effective inhibitor of the self-association of Stomatin, STOML1 and STOML2, but not podocin .
    OB-1-d3
  • HY-169998

    SARS-CoV Infection
    XJ5 is a non-nucleoside covalent inhibitor of Nsp12 (IC50=0.12 μM), which is the non-structural protein 12 of the virus. XJ5 has the potential to be an antiviral inhibitor of SARS-CoV-2 .
    XJ5
  • HY-162288
    FAZ-3532
    3 Publications Verification

    DNA/RNA Synthesis Cancer
    FAZ-3532 is a G3BP inhibitor (Kd = 0.54 μM) which binds to the NTF2L nsP3 binding pocket in G3BP1. FAZ-3532 disrupts the co-condensation of RNA, G3BP1, and caprin 1. FAZ-3532 inhibits G3BP-driven stress granule formation. FAZ-3532 can be studied as a powerful tool to probe the biology of stress granules and a promising interventions designed to modulate stress granule formation .
    FAZ-3532
  • HY-RS07525

    Small Interfering RNA (siRNA) Others

    LARGE2 Human Pre-designed siRNA Set A contains three designed siRNAs for LARGE2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    LARGE2 Human Pre-designed siRNA Set A
    LARGE2 Human Pre-designed siRNA Set A
  • HY-RS21879

    Small Interfering RNA (siRNA) Others

    Large2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Large2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Large2 Mouse Pre-designed siRNA Set A
    Large2 Mouse Pre-designed siRNA Set A
  • HY-RS28396

    Small Interfering RNA (siRNA) Others
    Large2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Large2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Large2 Rat Pre-designed siRNA Set A
    Large2 Rat Pre-designed siRNA Set A
  • HY-RS07524

    Small Interfering RNA (siRNA) Others

    LARGE1 Human Pre-designed siRNA Set A contains three designed siRNAs for LARGE1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    LARGE1 Human Pre-designed siRNA Set A
    LARGE1 Human Pre-designed siRNA Set A
  • HY-150623

    SARS-CoV Infection
    SARS-CoV-2 nsp13-IN-2 (Compound C2) is a SARS-CoV-2 non-structural protein 13 (nsp13) small-molecule inhibitor with an IC50 of 42 μM against nsp13 ssDNA + ATPase .
    SARS-CoV-2 nsp13-IN-2
  • HY-150624

    SARS-CoV Infection
    SARS-CoV-2 nsp13-IN-3 (Compound C3) is a SARS-CoV-2 non-structural protein 13 (nsp13) small-molecule inhibitor with an IC50 of 32 μM against nsp13 ssDNA + ATPase .
    SARS-CoV-2 nsp13-IN-3
  • HY-W107409

    Others Cancer
    Meridianin C is a marine natural product with anticancer activity. Meridianin C has significant inhibitory effects on four different human tongue cancer cells (YD-8, YD-10B, YD-38 and HSC-3). Meridianin C most strongly reduced the growth of YD-10B cells, the most aggressive and tumorigenic of the cell lines tested. Meridianin C also induced significant accumulation of large vesicles in YD-10B cells, validating its function through macrophagocytosis. Meridianin C reduces cellular levels of Dickkopf-related protein-3 (DKK-3), a known negative regulator of macrophagy. Meridianin C affects macrophagocytosis by downregulating DKK-3, thereby affecting cell proliferation .
    Meridianin C
  • HY-169102

    CHIKV Virus Protease Infection
    CHIKV nsP2 protease-IN-1(compound J13) is an oral active non-structural protein 2 protease inhibitor with the EC50 of 0.39 μM aganist of CHIKV S27. CHIKV nsP2 protease-IN-1 can be used for study of Chikungunya virus .
    CHIKV nsP2 protease-IN-1
  • HY-150632

    SARS-CoV Infection
    SARS-CoV-2 nsp13-IN-6 (compound C5) is a potent SARS-CoV-2 non-structural protein 13 (nsp13) inhibitor with IC50 values of 27 and 33 μM for ssDNA + ATPase and ssDNA - ATPase. SARS-CoV-2 nsp13-IN-6 can be used for researching anti-COVID-19 .
    SARS-CoV-2 nsp13-IN-6
  • HY-170649

    SARS-CoV Infection
    RdRP-IN-9 (Compound 6b) is a reversible covalent allosteric inhibitor of RdRp. RdRP-IN-9 demonstrates high anti-coronavirus activity, with an EC50 value of 0.68 μM against HCoV-OC43 RdRP-IN-9 exerts a more prolonged antiviral effect by reversibly acylating Cys12 in the NiRAN domain of non-structural protein 12 (nsp 12) and exhibits synergistic anti-coronavirus activity with Molnupiravir (HY-135853) .
    RdRP-IN-9
  • HY-150622

    SARS-CoV Infection
    SARS-CoV-2 nsp13-IN-1 (compound C1) is a potent nsp13 (non-structural protein 13) inhibitor. SARS-CoV-2 nsp13-IN-1 only inhibits nsp13 ssDNA + ATPase, with an IC50 of 6 μM. SARS-CoV-2 nsp13-IN-1 does not inhibit ssDNA - ATPase. SARS-CoV-2 nsp13-IN-1 can be used for COVID-19 research .
    SARS-CoV-2 nsp13-IN-1
  • HY-12594
    Paritaprevir
    10+ Cited Publications

    ABT-450; Veruprevir

    HCV Protease HCV SARS-CoV Infection
    Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) [3] .
    Paritaprevir
  • HY-171131

    Btk Cancer
    BTK-IN-41 (Compound 47) is the inhibitor for BTK with an IC50 of 5.4 nM. BTK-IN-41 inhibits the diffuse large B cell lymphoma cell TDM-8 with IC50 of 13.8 nM .
    BTK-IN-41
  • HY-12594A

    ABT-450 dihydrate; Veruprevir dihydrate

    HCV Protease HCV SARS-CoV Infection
    Paritaprevir (ABT-450) dihydrate is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir dihydrate is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.31 μM. Paritaprevir dihydrate is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir dihydrate can be enhanced by Ritonavir (a CYP450 inhibitor) [3] .
    Paritaprevir dihydrate
  • HY-P991345

    AMP-514

    PD-1/PD-L1 Cancer
    MEDI-0680 (AMP-514) is a human IgG4 monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. MEDI-0680 can be used in Diffuse Large B-Cell Lymphoma (DLBCL) research .
    MEDI-0680
  • HY-12594R

    HCV Protease HCV SARS-CoV Infection
    Paritaprevir (Standard) is the analytical standard of Paritaprevir. This product is intended for research and analytical applications. Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) [3] .
    Paritaprevir (Standard)
  • HY-132253

    Antibody-Drug Conjugates (ADCs) Cancer
    Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
    Polatuzumab vedotin
  • HY-132253A

    Antibody-Drug Conjugates (ADCs) Cancer
    Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL) .
    Polatuzumab vedotin (solution)
  • HY-150594

    IRAK NF-κB Cancer
    IRAK4-IN-17 (Compound 5) is a potent IRAK4 inhibitor with the IC50 of 1.3 nM . IRAK4-IN-17 can be used in large B-cell lymphoma (DLBCL) research .
    IRAK4-IN-17
  • HY-161080

    Nucleoside Antimetabolite/Analog Cancer
    4'-Ethynyl-2'-deoxycytidine is an anticancer nucleoside. 4'-Ethynyl-2'-deoxycytidine can used in study acute lymphoblastic leukemia and diffuse large B-cell lymphoma .
    4'-Ethynyl-2'-deoxycytidine
  • HY-P991544

    CD20 ADC Antibody Cancer
    TRS-005 Antibody is an antibody that targets CD20-positive tumor cells. TRS-005 Antibody can be used in the synthesis of antibody-drug conjugates (ADCs). TRS-005 Antibody can be used in the study of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) .
    TRS-005 Antibody
  • HY-10300
    Narlaprevir
    5 Publications Verification

    SCH 900518

    HCV HCV Protease SARS-CoV Infection
    Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a Ki value of 6 nM and an EC90 value of 40 nM . Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease . Narlaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.3 μM [3].
    Narlaprevir
  • HY-155574

    IRAK Apoptosis Cancer
    IRAK4-IN-27 (Compound 22) is a potent, selective inhibitor of IRAK4, with IC50 of 8.7 nM. IRAK4-IN-27 inhibits cell growth, and promotes apoptosis in MYD88 L265P diffuse large B-cell lymphoma (DLBCL) cell line. IRAK4-IN-27 can be used for DLBCL study .
    IRAK4-IN-27
  • HY-131246

    Histone Methyltransferase Cancer
    DM-01 is a powerful and selective EZH2 inhibitor for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and SNF5/INI-1/SMARCB1 genetically defined solid tumors .
    DM-01
  • HY-12422

    CDK Cancer
    Voruciclib is an orally active and selective CDK inhibitor with Ki values of 0.626 nM-9.1 nM. Voruciclib potently blocks CDK9, the transcriptional regulator of MCL-1. Voruciclib represses expression of MCL-1 in multiple models of diffuse large B-cell lymphoma (DLBCL) .
    Voruciclib
  • HY-12422A

    CDK Cancer
    Voruciclib hydrochloride is an orally active and selective CDK inhibitor with Ki values of 0.626 nM-9.1 nM. Voruciclib hydrochloride potently blocks CDK9, the transcriptional regulator of MCL-1. Voruciclib hydrochloride represses expression of MCL-1 in multiple models of diffuse large B-cell lymphoma (DLBCL) .
    Voruciclib hydrochloride
  • HY-144858
    EZM0414
    5+ Cited Publications

    Histone Methyltransferase Cancer
    EZM0414 is a potent, selective, orally bioavailable inhibitor of SETD2 (IC50=18 nM in SETD2 biochemical assay; IC50=34 nM in cellular assay). EZM0414 can be used for the research of relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma .
    EZM0414
  • HY-10300R

    SCH 900518 (Standard)

    Reference Standards HCV HCV Protease SARS-CoV Infection
    Narlaprevir (Standard) is the analytical standard of Narlaprevir. This product is intended for research and analytical applications. Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a Ki value of 6 nM and an EC90 value of 40 nM . Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease . Narlaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.3 μM [3].
    Narlaprevir (Standard)
  • HY-145734A

    Microtubule/Tubulin Cancer
    AMXI-5001 hydrochloride is a potent, orally active, and dual parp1/2 and microtubule polymerization inhibitor. MXI-5001 hydrochloride exhibits selective antitumor cytotoxicity across a wide variety of human cancer cells with much lower IC50s than existing clinical PARP1/2 inhibitors. AMXI-5001 hydrochloride induces complete regression of established tumors, including exceedingly large tumors .
    AMXI-5001 hydrochloride
  • HY-145734

    Microtubule/Tubulin Cancer
    AMXI-5001 is a potent, orally active, and dual parp1/2 and microtubule polymerization inhibitor. MXI-5001 exhibits selective antitumor cytotoxicity across a wide variety of human cancer cells with much lower IC50s than existing clinical PARP1/2 inhibitors. AMXI-5001 induces complete regression of established tumors, including exceedingly large tumors .
    AMXI-5001
  • HY-P99349

    Loncastuximab tesirine-lpyl; ADCT-402

    Antibody-Drug Conjugates (ADCs) Apoptosis Cancer
    Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). The antibody portion is Loncastuximab (HY-P99711), and the drug-linker conjugate for ADC is Tesirine (HY-128952). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma .
    Loncastuximab tesirine
  • HY-14775
    Nesbuvir
    5+ Cited Publications

    HCV-796

    HCV Infection
    Nesbuvir is a nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase.
    Nesbuvir
  • HY-146408

    Anaplastic lymphoma kinase (ALK) Cancer
    ALK-IN-21 (Compound B10), a potent ALK inhibitor for ALKG1202R mutation, exhibits remarkable enzymatic inhibitory potency with IC50 values of 4.59 nM, 2.07 nM and 5.95 nM toward ALK WT, ALK L1196M and ALK G1202R, respectively. ALK-IN-21 efficiently inhibits the proliferation of ALK-positive Karpas299 and H2228 cells both with IC50 values of 0.07 μM. ALK-IN-21 can be used for the research of anaplastic large cell lymphoma .
    ALK-IN-21
  • HY-19916A

    BAL-101553 dihydrochloride

    Microtubule/Tubulin Checkpoint Kinase (Chk) Cancer
    Lisavanbulin (BAL-101553) dihydrochloride is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin dihydrochloride exhibits antitumor activity, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin dihydrochloride has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin dihydrochloride is also a spindle assembly checkpoint activator. Lisavanbulin dihydrochloride induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin dihydrochloride can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma [3] .
    Lisavanbulin dihydrochloride
  • HY-P4882

    Amyloid-β Neurological Disease
    (Pyr3)-Amyloid β-Protein (3-42) is the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. (Pyr3)-Amyloid β-Protein (3-42) is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits .
    (Pyr3)-Amyloid β-Protein (3-42)
  • HY-19916

    BAL-101553

    Microtubule/Tubulin Checkpoint Kinase (Chk) Cancer
    Lisavanbulin (BAL-101553) is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin is a BBB-penetrant and orally active antitumor agent, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin is also a spindle assembly checkpoint activator. Lisavanbulin induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma [3] .
    Lisavanbulin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: